News from shire plc A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages

Latest

22 Jun, 2017, 06:00 BST Shire Announces EMA Validation of Veyvondi[TM] [Von Willebrand Factor (Recombinant)] Marketing Authorization Application for Treatment of Von Willebrand Disease

VEYVONDI is the first and only recombinant von Willebrand factor treatment for adults with von Willebrand disease, the most common inherited bleeding ...


19 May, 2017, 06:00 BST Shire to Highlight New Research Into Chronic Hypoparathyroidism at the European Congress of Endocrinology

New clinical and real-life data in chronic hypoparathyroidism, to advance understanding of this rare disease and improve patients' lives Shire plc...


18 May, 2017, 14:00 BST The Lancet Publishes Phase 2 Results from Shire's Investigational Anti-MAdCAM Antibody Showing Significantly Increased Remission Rates in Patients with Moderate-to-Severe Ulcerative Colitis

Study met primary endpoint demonstrating significantly greater remission rates in patients receiving anti-MAdCAM antibody (SHP647) compared to...


18 May, 2017, 12:00 BST Shire's Investigational Treatment Lanadelumab Reduces Hereditary Angioedema Monthly Attack Rate by 87% Versus Placebo in Phase 3 26-week Pivotal Trial

Significant reduction in monthly Hereditary Angioedema (HAE) attack rate with infrequent subcutaneous administration Data to serve as basis for U.S....


02 May, 2017, 12:00 BST Shire Delivers Strong Q1 2017 Revenue Growth While Advancing Late-stage Pipeline

Commercial execution, efficiency improvements, and debt pay-down remain top priorities Shire plc (Shire) (LSE: SHP, NASDAQ: SHPG) announces unaudited ...


01 May, 2017, 12:00 BST Shire and Parion Sciences Enter into a Collaborative License Agreement to Advance P-321 for Ophthalmic Indications

Demonstrates ongoing commitment to innovation in ophthalmics for Shire P-321 is a Phase 2 investigational topical treatment for dry eye disease Shire ...


26 Apr, 2017, 06:00 BST Shire Granted EU Conditional Marketing Authorisation for Natpar[®▼] (Parathyroid Hormone) for the Treatment of Patients with Chronic Hypoparathyroidism

Natpar is the first and only licensed recombinant human parathyroid hormone therapy for chronic hypoparathyroidism Shire plc (LSE: SHP, NASDAQ: SHPG) ...


25 Apr, 2017, 12:00 BST Shire to Participate at the Deutsche Bank 42nd Annual Health Care Conference

Shire plc (LSE: SHP, NASDAQ: SHPG) announces that Jeff Poulton, Chief Financial Officer, will participate at the Deutsche Bank 42nd annual health...


24 Apr, 2017, 06:00 BST Shire Launches #PIPostsThanks Social Campaign to Raise Awareness of Primary Immunodeficiency (PI)

Shire launches campaign to raise global awareness during World PI Week Shire plc (LSE: SHP, NASDAQ: SHPG), the global leader in rare diseases, is...


17 Apr, 2017, 06:00 BST Shire plc: Data Show A Bleeding Episode Occurs Every Three to 15 Seconds in People Living With Hemophilia Worldwide

On World Hemophilia Day 2017, Shire challenges the community to collectively improve global standards of care for rare bleeding disorders Shire plc...


30 Mar, 2017, 09:41 BST INTUNIV® (Guanfacine Hydrochloride Prolonged Release), a Non-stimulant for the Treatment of ADHD, Receives Approval in Japan

A New Non-stimulant Clinical Option for Children and Adolescents From 6 to 17 Years old With ADHD Shire plc (LSE: SHP, NASDAQ: SHPG) today announced...


16 Mar, 2017, 06:00 GMT Shire Receives European Approval for Label Extension of CINRYZE®▼(C1 inhibitor [human]) to Prevent and Treat Hereditary Angioedema (HAE) Attacks in Paediatric Patients with HAE

CINRYZE is now the first and only Hereditary angioedema treatment approved for routine prevention in paediatrics Shire plc (LSE: SHP, NASDAQ: SHPG)...


01 Mar, 2017, 12:00 GMT Shire to Participate at the Cowen 37th Annual Healthcare Conference

Shire plc (LSE: SHP, NASDAQ: SHPG) announces that Jeff Poulton, Chief Financial Officer, will participate at the Cowen 37th Annual Healthcare...


24 Feb, 2017, 12:17 GMT CHMP Recommends EU Conditional Marketing Authorisation for Natpar® (Parathyroid Hormone) for Patients with Chronic Hypoparathyroidism

This Press Release is intended for Global Use If approved, Natpar would be the first licensed recombinant parathyroid hormone in Europe for the...


23 Feb, 2017, 09:17 GMT New England Journal of Medicine Publishes Phase 1b Results for Shire's Investigational Treatment for Hereditary Angioedema, a Rare Genetic Disease

Results Served as Basis for Ongoing Phase 3 Trial Shire plc (LSE: SHP, NASDAQ: SHPG), the global leader in rare diseases, today announced the...


23 Feb, 2017, 07:00 GMT Shire Launches 'Rare Count' Campaign to Personalize the Global Impact of Rare Diseases

- For Every 'Count', Shire Will Donate to Leading Rare Disease Organizations - Campaign Honoring Rare Disease Day Open to All at...


16 Feb, 2017, 12:52 GMT Shire Reports Full Year 2016 Results With Record Revenue; Positioned for Continued Strong Growth Driven by Best-in-class Rare Disease Pipeline

Key growth contributions from all therapeutic areas Baxalta integration progressing ahead of schedule; Shire now the world leader in rare diseases...


07 Feb, 2017, 20:42 GMT Shire Responds to U.S. Federal Trade Commission Civil Action

Shire plc (Shire) (LSE: SHP, NASDAQ: SHPG) acknowledges the decision announced today by the U.S. Federal Trade Commission ("FTC") to file a civil...


01 Feb, 2017, 18:36 GMT New Data From Shire Aim To Help Close the Diagnosis and Treatment Gap for People With Hemophilia

Shire presentations at EAHAD 2017 underscore the company's leadership in improving global standards of care Shire plc (LSE: SHP, NASDAQ: SHPG), the...


19 Jan, 2017, 12:00 GMT U.S. FDA Acknowledges Receipt of Shire's New Drug Application for SHP465 for ADHD

Shire plc (LSE: SHP, NASDAQ: SHPG) announced that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of the Class 2 resubmission of ...


04 Jan, 2017, 14:30 GMT Shire to Present at the 35th Annual J.P. Morgan Healthcare Conference

Shire plc (LSE: SHP, NASDAQ: SHPG) announces that Flemming Ornskov, MD, Chief Executive Officer, will present at the 35th Annual J.P. Morgan...


27 Dec, 2016, 12:00 GMT Shire Announces FDA Approval of Adynovate® [Antihemophilic Factor (Recombinant), Pegylated] for use in Children and Surgical Settings

New FDA-approved indications for ADYNOVATE provides more hemophilia A patients access to proven prophylaxis with a simple, twice-weekly dosing...


02 Dec, 2016, 22:21 GMT Shire Reports on Four Decades of Real-World Safety Experience With FEIBA® [Anti-Inhibitor Coagulant Complex]

Shire plc (LSE: SHP; NASDAQ: SHPG), the leading biotechnology company focused on serving individuals with rare diseases, is presenting an update on...


02 Dec, 2016, 16:02 GMT Topline Results of Phase 3 Investigational Study of VONVENDI™ [von Willebrand factor (recombinant)] Meets Primary Endpoint Effectively Controlling Bleeding and Blood Loss During Surgical Procedures

Results will form the basis of a supplemental new drug application to the U.S. Food & Drug Administration, requesting an expanded indication for...


16 Nov, 2016, 12:00 GMT Shire Launches CUVITRU[TM] [Immune Globulin Subcutaneous (Human), 20% Solution] in the U.S. for Primary Immunodeficiency

CUVITRU, now available in the U.S., expands Shire's immunoglobulin portfolio of treatment options to meet the unique needs of children and adults...